glp-1 Archives - Vista Partners LLC | HomeVista Partners LLC

From Waistlines to Warheads: How GLP‑1 Cash Is Quietly Fueling the Radiopharma Revolution -( $AZN $BMY $LLY )

by John F. Heerdink, Jr. April 20, 2026 194Views 0Likes

Eli Lilly is turning its GLP-1 windfall into a broader oncology and radiopharma push, just as a new generation of targeted alpha therapies steps onto center stage with companies like NAYA Therapeutics — and investors are starting to notice that “weight loss”…

From Shopping Carts to Smart Carts: Walmart’s Digital Health Push Meets Lilly’s GLP‑1 Boom – ( $AMGN $LLY $MODD $NVO $PFE $WMT )

by John F. Heerdink, Jr. April 20, 2026 129Views 0Likes

Walmart’s (WMT) latest move into digital health reads less like a retail side-hustle and more like an opening bell in the next leg of the GLP‑1 trade, with syringes, smartphones, and stock tickers all lining up on aisle 7. As weight‑loss drugs…

The Diabesity Gold Rush: GLP‑1 Giants and a Tiny Patch Pump Hunting for XXL Returns -( $AMGN GS $LLY $MODD $NVO )

by John F. Heerdink, Jr. April 8, 2026 275Views 0Likes

The global “diabesity” market is swelling into a once‑in‑a‑generation opportunity, and Eli Lilly, Novo Nordisk—and now a new class of device innovators like Modular Medical (NASDAQ: MODD)—are still lacing up their running shoes rather than sprinting for the finish line. For investors,…

Merck’s Nearly $6 Billion Terns Buyout Deal Signals Big Pharma’s Next Act in Cancer—and Obesity? -( $MRK $TERN $LLY $NVS $IBB $XBI )

by John F. Heerdink, Jr. March 25, 2026 510Views 0Likes

Merck (MRK) is preparing to spend nearly $6 billion in cash to acquire Terns Pharmaceuticals (TERN), a move that reads like a carefully scripted sequel to its Keytruda blockbuster rather than an impulsive spin-off. The price represents a premium to Terns’ roughly…

The Big Mac Meets the Skinny Pill: How McDonald’s and Eli Lilly Are Sharing the Same Consumer -( $LLY $MCD )

by John F. Heerdink, Jr. February 12, 2026 469Views 0Likes

McDonald’s (MCD) has handled low-carb fads, kale revolutions, and the brief reign of cauliflower rice, but its newest rival comes with a prescription label and a co-pay. GLP-1 weight-loss medicines—from injectables like Eli Lilly’s (LLY) Mounjaro and Zepbound to the next wave…

Eli Lilly’s Weight-Loss Empire Just Got Heavier with $2.4B Acquisition – And So Did Its Market Cap -( $LLY $NVO $SPY )

by John F. Heerdink, Jr. February 9, 2026 363Views 0Likes

Eli Lilly (LLY) has once again muscled its way to the top of the healthcare league tables, with its stock climbing as investors double down on the idea that obesity drugs are less a fad and more a new asset class. The…

Tag: glp-1

From Waistlines to Warheads: How GLP‑1 Cash Is Quietly Fueling the Radiopharma Revolution -( $AZN $BMY $LLY )

From Shopping Carts to Smart Carts: Walmart’s Digital Health Push Meets Lilly’s GLP‑1 Boom – ( $AMGN $LLY $MODD $NVO $PFE $WMT )

The Diabesity Gold Rush: GLP‑1 Giants and a Tiny Patch Pump Hunting for XXL Returns -( $AMGN GS $LLY $MODD $NVO )

Merck’s Nearly $6 Billion Terns Buyout Deal Signals Big Pharma’s Next Act in Cancer—and Obesity? -( $MRK $TERN $LLY $NVS $IBB $XBI )

The Big Mac Meets the Skinny Pill: How McDonald’s and Eli Lilly Are Sharing the Same Consumer -( $LLY $MCD )

Eli Lilly’s Weight-Loss Empire Just Got Heavier with $2.4B Acquisition – And So Did Its Market Cap -( $LLY $NVO $SPY )

Your Guide To Staying Informed In The Markets